Zevra Therapeutics, Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$10.20
FAIR PRICE
$15.16
MARGIN
$4.96
NOW AVAILABLE
Get notified when ZVRA's fair price changes
Push notifications when ZVRA's valuation shifts. Available on iOS and Android.
FPI RATING
Consistent growth trajectory and low debt levels, but volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$12.13
Fair price × 0.80
DISTANCE
18.9%
Price to entry level
At the current price of $10.20, ZVRA trades 18.9% below the conservative entry level of $12.13. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate ZVRA's fair price
Zevra Therapeutics, Inc.'s fair price of $15.16 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $10.20, ZVRA trades 48.6% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting ZVRA's risk profile.
RELATIVE · 30%
Comparing ZVRA's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for ZVRA, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate ZVRA's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for ZVRA.
Explore on BuliosFAQ
What is the fair price of ZVRA?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Zevra Therapeutics, Inc. is $15.16. At the current market price of $10.20, ZVRA trades 48.6% below its calculated fair value.
Is ZVRA overvalued or undervalued?+
Zevra Therapeutics, Inc. is currently undervalued based on our valuation model. The stock trades at $10.20, which is 48.6% below the fair price of $15.16. The P/E ratio of 6.8x is a key metric in the valuation.
What is the margin of safety for ZVRA?+
With a 20% margin of safety applied to the fair price of $15.16, the conservative entry level for ZVRA is $12.13. At the current market price of $10.20, the stock trades 18.9% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is ZVRA's fair price updated?+
We update fair price calculations for ZVRA daily after market close. The current fair price of $15.16 incorporates the latest market data and sector multiples.
What factors affect ZVRA's fair price calculation?+
ZVRA's fair price of $15.16 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 6.8x, ROE of 73.9%.
Is ZVRA a good buy right now?+
At $10.20, ZVRA trades 48.6% below our fair value estimate of $15.16. The stock is currently undervalued. ROE stands at 73.9% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does ZVRA pay dividends?+
ZVRA does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.